Vertex Pharmaceuticals
VRTX
708 hedge funds and large institutions have $41.8B invested in Vertex Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 288 increasing their positions, 237 reducing their positions, and 71 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 288 | Existing positions reduced: 237
20% more funds holding in top 10
Funds holding in top 10: 15 → 18 (+3)
0.31% less ownership
Funds ownership: 96.23% → 95.92% (-0.31%)
8% less first-time investments, than exits
New positions opened: 65 | Existing positions closed: 71
1% less funds holding
Funds holding: 716 → 708 (-8)
8% less capital invested
Capital invested by funds: $45.2B → $41.8B (-$3.4B)
18% less call options, than puts
Call options by funds: $253M | Put options by funds: $307M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HL
Harding Loevner
Bridgewater,
New Jersey
|
+$280M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$248M |
| 3 |
Janus Henderson Group
London,
|
+$145M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$122M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$102M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$170M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$153M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$127M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$125M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$84.7M |
VRTX Hedge Fund Activity: Q3 2019 in Review
708 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2019, worth a combined $41.8B — down 7.5% from $45.2B a quarter earlier.
Sellers outnumbered buyers: 71 funds closed out of VRTX and 65 opened new positions — a net loss of 6 holders — while 237 trimmed existing stakes and 288 added.
The largest buyer was Harding Loevner, adding an estimated $280M. The largest seller was JP Morgan Chase, cutting an estimated $170M.
- 708 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2019, down from 716 in Q2 2019.
- Funds reported $41.8B of Vertex Pharmaceuticals stock for Q3 2019, down 7.5% quarter-over-quarter.
- 65 funds opened new Vertex Pharmaceuticals positions in Q3 2019 and 71 closed out, a net change of -6 holders.
- The largest Vertex Pharmaceuticals buyer in Q3 2019 was Harding Loevner, an estimated $280M added.
- The largest Vertex Pharmaceuticals seller in Q3 2019 was JP Morgan Chase, an estimated $170M sold.
Based on aggregated 13F filings for Q3 2019.